+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer



Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer



Cancer ChemoTherapy and Pharmacology 68(6): 1413-1419



Most of the cancer chemotherapy treatments employ drugs in combination. For combination treatments, it is relevant to assess interaction between two or more anticancer agents used in clinics. Based on clinical data and using modeling techniques, the work analyzes the pharmacodynamic interaction between capecitabine and docetaxel used in combination in metastatic breast cancer. We developed mathematical models to describe tumor growth inhibition profile under treatment based on Phase II and Phase III clinical data of capecitabine and docetaxel in metastatic breast cancer. Model parameters were estimated by population approach with NONMEM(®) on single-agent and combination data. Simulations were performed using MATLAB. Capecitabine and docetaxel combination in metastatic breast cancer results in a synergistic effect as compared with the simple additive effects of single-agent treatments. Docetaxel is more efficient than capecitabine at the start of treatment but develops resistance faster. Modeling revealed no resistance of capecitabine for the combination data. Modeling could be a powerful tool to design the most advantageous combination regimen for capecitabine and docetaxel in metastatic breast cancer in order to increase the time before regrowth and decrease the tumor size at regrowth.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036063710

Download citation: RISBibTeXText

PMID: 21476101

DOI: 10.1007/s00280-011-1628-6


Related references

Docetaxel and capecitabine in metastatic androgen independent prostate cancer (AIPC): Phase II trial to detect clinical efficacy of a synergistic combination. Journal of Clinical Oncology 23(16_suppl): 4703-4703, 2016

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters 10(4): 2598-2602, 2015

Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France. Bulletin du Cancer 92(9): 809-816, 2005

Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clinical Breast Cancer 5(4): 287-292, 2004

Capecitabine in combination with docetaxel in the management of metastatic breast cancer. Journal of Clinical Oncology 26(15_suppl): 12016-12016, 2016

Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer. Breast Cancer 11(2): 116-120, 2004

Population based cost-effectiveness analysis of combination capecitabine and docetaxel versus single agent docetaxel in the treatment of metastatic breast cancer following an anthracycline regimen. European Journal of Cancer 38(Supplement 3): S67, March, 2002

Survival update of so14999 a large phase III trial of capecitabine/docetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced or metastatic breast cancer. European Journal of Cancer 37(Supplement 6): S151, October, 2001

Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer. Beijing Da Xue Xue Bao. Yi Xue Ban 43(1): 151-156, 2012

Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 12(4): 375-389, 2007

Capecitabine and docetaxel in the treatment of metastatic breast cancer combination, sequence or single agent?. EJC Supplements 6(8): 5-8, 2008

Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer. Zhonghua Zhong Liu Za Zhi 30(12): 944-946, 2010

Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients. Current Topics in Medicinal Chemistry 12(15): 1665-1668, 2013

Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast 22(6): 1087-1093, 2014

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study. Pathology Oncology Research 23(3): 505-511, 2016